LONDON, June 10, 2020
Huma enables the NHS's digital transformation unit NHSX to support 'Virtual Wards' to monitor and care for patients with moderate symptoms of COVID-19 while in isolation
Project aims to see how healthcare teams can get patients to hospitals at the right times for better outcomes, better support early intervention to avoid patients needing ITU care and help to prevent virus spread
LONDON, June 10, 2020 /PRNewswire/ -- Huma is working with the NHS's digital transformation unit NHSX to provide remote monitoring for COVID-19 patients who are at-home, in quarantine, or self-isolating. Developed with leading international clinicians and academics, Huma has worked with NHSX and local NHS organisations to configure and trial its Medopad COVID-19 remote patient monitoring (RPM) platform in six sites to help support the response to the COVID-19 pandemic.
Creating Virtual Wards
A number of NHS sites are now working with Huma's solution to support Virtual Wards to monitor and care for patients. Medopad enables the accurate exchange of health data and information between patients and their NHS care team. Healthcare teams can closely monitor a patient's symptoms to advise on appropriate care and early intervention, staying informed of symptoms and being alerted to disease progression that could avoid further complications or prompt a diagnostic procedure or a visit from a clinician or a visit to hospital – if needed.
Tara Donnelly, Chief Digital Officer, NHSX said: "This is a great example of how new technology is supporting healthcare professionals to provide the right care at the right time. With COVID-19, it's vital that we make use of digital tools that can help support patients who don't need immediate hospital care and allow close monitoring of their condition.
"The feedback we are getting from patients is that the remote monitoring with clinical oversight is really reassuring to them, and they are grateful to be at home while they recover, rather than in a hospital bed. The clinical team is finding it helps give them very rapid feedback on their patients and they are able to keep an eye on a number of people at a glance, which is working much better for them than the previous system which relied on phone calls."
The COVID-19 remote monitoring trial phase started in London and Hertfordshire in both primary and secondary care settings to support patients with COVID-19 symptoms.
The initial projects were:
Dr. Matthew Knight, Respiratory Consultant at Watford General Hospital, said: "Our teams are working to provide the best care for patients with COVID-19 symptoms around the clock. To provide the best patient care and outcomes, protect the NHS and prevent community spread, the remote patient monitoring offers a promising solution to help us scale our efforts to the growing needs of our community."
Tony Willis, Clinical Director for Diabetes at North West London Collaboration of CCGs, said: "Patients with suspected COVID-19 can deteriorate in a matter of hours. That's why it's vital that clinicians can track their symptoms and vital signs regularly so that they can intervene if there is significant deterioration. But patients do not have to be at the hospital or clinic all the time and this new solution means we can capture patient health data frequently enough to take timely action while the patient is in the comfort of their own home."
Within weeks, teams from the three initial sites, NHSX and Huma went from concept and ideation to implementation, quickly and collaboratively developing several iterations of the app to meet local requirements and work across systems. Huma's team needed only eight days to create the tech requirements to get up and running, configuring modules (such as patient questionnaires and symptom tracking) and user flows with clinicians at the trial sites to customise clinical pathways. Healthcare practitioners at the local sites were trained on using the Medopad solution on 17 April and the project has since been rolling out to patients.
Dan Vahdat, founder and CEO of Huma, said: "As a British company, we can think of no greater honour than being part of this pilot that is helping three NHS trial sites respond to the COVID-19 pandemic in this hour of need. We are proud to use the learnings we've developed with our NHS partners to provide care for many COVID-19 patients to help people support the NHS and save lives."
Aida Yousefi, Chief Commercial Officer of Huma, said: "NHS staff are working tirelessly to provide care during this crisis. It is an honour to have the opportunity to trial our technology to lessen their burden at these sites by providing the reassurance that their patients are being monitored accurately and appropriately.
"Equally, isolated and worried patients in the community can have the reassurance that they are being looked after remotely and appropriately by their healthcare teams. It has been a privilege to work with NHSX. Together we have worked at speed to implement in less than three weeks."
Huma, headquartered in London, is providing its Medopad COVID-19 RPM solution as a not-for-profit initiative.
Huma partners with scientists, technologists and healthcare professionals to understand, treat and ultimately prevent ill health. Giving knowledge and power to those with medical conditions, while saving clinicians time, energy and valuable resources. Because, by collectively benefiting from the data we individually generate, we can all live our longest, fullest lives. www.huma.com
Press kit available here: https://bit.ly/HumaPressKit
How Huma's Medopad COVID-19 RPM platform works:
Medopad Healthcare Practitioner telemedicine portal features:
Medopad patient app features
Medopad's COVID-19 RPM solution is configured to monitor and flag deterioration in COVID-19 patients. It supports self-management through a simple analytics dashboard. It only requires an iOS or Android smartphone, and can also be combined with other devices (such as an oximeter). Patients submit symptom ratings once per day. Each symptom is rated by the patient as mild, moderate, severe or very severe. The app is prescribed by clinicians to COVID-19 positive patients.
The Medopad patient app modules for the trial include: